This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Galectin: Mark The Date. Drug Data Are Coming And We're Selling Stock.

03/25/14 - 01:29 PM EDT

How to promote your stock, Galectin style.


Don't Hate Josh Brown For Calling Biotech a Bubble. Learn From Him.

03/24/14 - 04:17 PM EDT

If you want to understand why your beloved biotech stocks are tanking, you must read Brown's blog post right now. Hell, if you already read Brown's post earlier today, read it again.


Another Bad Day in Biotech Stocks, Pace of Selling Accelerates

03/24/14 - 11:21 AM EDT

Bubble or not, biotech stocks have been weak all March, erasing gains made in February.


Biotech Stocks Weak on Fear That Gilead Drug Pricing Woes Will Spread

03/21/14 - 02:02 PM EDT

Investors are spooked that heightened scrutiny over Gilead's Hep C drug will cause a backlash across the entire biotech sector.


Read This Twitter Chat About Gilead and the Cost of its Hep C Drug

03/20/14 - 05:54 PM EDT

Bloomberg's Drew Armstrong and ISI Group's Mark Schoenebaum discuss Gilead, Sovaldi and the controversy of Medicaid reimbursement.


MannKind's Most Financially Conflicted Sell-Side Analyst Loves Afrezza

03/18/14 - 03:22 PM EDT

When your job is helping MannKind sell stock, it's not hard to be a bull.


Prosensa Making the Best of Inconsistent Drisapersen Data

03/18/14 - 11:03 AM EDT

With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.


New Heart Safety Report Caused Intercept Pharma's Friday Night Stumble

03/14/14 - 08:04 PM EDT

Intercept discloses cardiovascular events reported in a study of the company's fatty liver disease drug.


The Bull Case for Gilead Amidst Recent Hep C Sales Cliff Worries

03/14/14 - 12:45 PM EDT

Gilead has transformed itself with tremendous success twice already and is now working on plan number three.


Investors Deserve Answers From Galena and Cytrx About Involvement in Stock Promotion Scheme

03/14/14 - 10:54 AM EDT

Richard Pearson's expose, published yesterday on Seeking Alpha, pulls back the curtain on the shady world of paid stock touts. It's an excellent, well-researched story, mostly because of the documentation (emails and electronic signatures) Pearson obtained linking executives at Cytrx and Galena Biopharma to the publication of promotional articles under assumed names and without proper financial disclosure.


Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -


DOW 16,563.30 -317.06 -1.88%
S&P 500 1,930.67 -39.40 -2.00%
NASDAQ 4,369.7730 -93.1290 -2.09%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs